Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.
MAT2203
Mucor
Rhizopus
amphotericin B
antifungal agents
lipid nanocrystal
liposomal amphotericin B
mucormycosis
murine
oral amphotericin B
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
Invasive mucormycosis (IM) is associated with high mortality and morbidity. MAT2203 is an orally administered lipid nanocrystal formulation of amphotericin B, which has been shown to be safe and effective against other fungal infections. We sought to compare the efficacy of MAT2203 to liposomal amphotericin B (LAMB) treatment in a neutropenic mouse model of IM due to
Identifiants
pubmed: 38687015
doi: 10.1128/aac.01540-23
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM